KLRS Q3 2024 Earnings — Kalaris Therapeutics Inc Revenue & Financial Results | Market Cap Arena

KLRSKalaris Therapeutics Inc

$187M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$38M

Net Income

-$38M

EPS (Diluted)

$-7.64

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$262,000

Balance Sheet

Total Assets

$2M

Total Liabilities

$92M

Stockholders' Equity

-$89M

Cash & Equivalents

$2M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$4M	+100.0%
Operating Income	-$38M	-$47M	+19.4%
Net Income	-$38M	-$44M	+14.0%